Isis' Balancing Act: Diversify With Cancer, But Avoid High-Stakes Gambles
Executive Summary
Isis tried a delicate balancing act during its May 20 pipeline update: it sought to accentuate its progress in branching out into cancer drug development, while also reassuring investors that its oncology spend is relatively modest and doesn't introduce major risk
You may also be interested in...
Isis Reacquires Cancer Compound From Lilly To Develop In-House
Lilly holds option to reacquire LY2275796 at the start of Phase III.
Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger
Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011